PLD1 and glioblastoma: Targeting PLD1 attenuates intestinal tumorigenesis by blocking phosphoinositide 3‐kinase/Akt and Wnt/β‐catenin signaling pathways [4], which are associated with glioma development and poor prognosis of GBM patients [14].